IFIT5

Summary

IFIT5 (interferon induced protein with tetratricopeptide repeats 5, HGNC:13328) is a protein-coding gene on chromosome 10q23.31, encoding Interferon-induced protein with tetratricopeptide repeats 5 (Q13325). Interferon-induced RNA-binding protein involved in the human innate immune response.

Enables RNA binding activity and double-stranded DNA binding activity. Involved in defense response to virus; negative regulation of viral genome replication; and positive regulation of canonical NF-kappaB signal transduction. Located in several cellular components, including IkappaB kinase complex; actin cytoskeleton; and ruffle membrane.

Source: NCBI Gene 24138 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 54 total
• MANE Select transcript: NM_012420

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13328
Approved symbol	IFIT5
Name	interferon induced protein with tetratricopeptide repeats 5
Location	10q23.31
Locus type	gene with protein product
Status	Approved
Aliases	RI58
Ensembl gene	ENSG00000152778
Ensembl biotype	protein_coding
OMIM	616135
Entrez	24138

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 6 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000371795, ENST00000679632, ENST00000680591, ENST00000681163, ENST00000681270, ENST00000681348, ENST00000681359, ENST00000681422

RefSeq mRNA: 1 — MANE Select: NM_012420 NM_012420

CCDS: CCDS7403

Canonical transcript exons

ENST00000371795 — 2 exons

Exon	Start	End
ENSE00001456120	89417205	89420997
ENSE00001456123	89414568	89414803

Expression profiles

Bgee: expression breadth ubiquitous, 274 present calls, max score 92.19.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 20.6441 / max 354.5567, expressed in 1717 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
106148	10.6947	1491
106151	8.4829	1609
106150	0.9762	626
106149	0.3963	106
106147	0.0940	37

Top tissues by expression

291 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	92.19	gold quality
buccal mucosa cell	CL:0002336	91.17	gold quality
CA1 field of hippocampus	UBERON:0003881	90.17	gold quality
endothelial cell	CL:0000115	89.74	gold quality
palpebral conjunctiva	UBERON:0001812	89.44	gold quality
decidua	UBERON:0002450	89.07	gold quality
pons	UBERON:0000988	88.69	gold quality
choroid plexus epithelium	UBERON:0003911	88.50	gold quality
superior vestibular nucleus	UBERON:0007227	88.35	gold quality
heart right ventricle	UBERON:0002080	88.28	gold quality
trigeminal ganglion	UBERON:0001675	87.89	gold quality
pericardium	UBERON:0002407	87.79	gold quality
inferior olivary complex	UBERON:0002127	87.57	gold quality
mucosa of paranasal sinus	UBERON:0005030	87.28	silver quality
medulla oblongata	UBERON:0001896	87.16	gold quality
substantia nigra pars compacta	UBERON:0001965	86.86	gold quality
cauda epididymis	UBERON:0004360	86.74	gold quality
caput epididymis	UBERON:0004358	86.63	gold quality
cranial nerve II	UBERON:0000941	86.53	gold quality
islet of Langerhans	UBERON:0000006	86.38	gold quality
synovial joint	UBERON:0002217	86.12	gold quality
visceral pleura	UBERON:0002401	85.86	gold quality
dorsal root ganglion	UBERON:0000044	85.81	gold quality
metanephric glomerulus	UBERON:0004736	85.60	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	85.58	gold quality
orbitofrontal cortex	UBERON:0004167	85.57	silver quality
renal glomerulus	UBERON:0000074	85.56	gold quality
nephron tubule	UBERON:0001231	85.55	gold quality
Brodmann (1909) area 23	UBERON:0013554	85.53	gold quality
lower lobe of lung	UBERON:0008949	85.27	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

117 targeting IFIT5, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-1236-3P	99.94	68.04	1695
HSA-MIR-552-5P	99.93	68.56	1583
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-539-5P	99.93	70.30	2855
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-374A-5P	99.90	71.34	2923

Literature-anchored findings (GeneRIF, showing 10)

• IFIT5 recognizes cellular RNA instead of protein partners. (PMID:23317505)
• crystal structures of human IFIT5, its complex with PPP-RNAs, and an amino-terminal fragment of IFIT1 (PMID:23334420)
• IFIT5 consists of 24 alpha-helices that pack into a special “V”-like structure. (PMID:23774268)
• TRIF-N-terminal helical domain shares structural similarity with IFIT5. (PMID:24311583)
• show that IFIT5 binds precursor and processed tRNAs, as well as other RNA polymerase III transcripts. Our findings establish the RNA recognition specificity of the human innate immune response protein IFIT5 (PMID:25092312)
• IFIT5 promotes SeV-induced IKK phosphorylation and NF-kappaB activation by regulating the recruitment of IKK to TAK1. (PMID:26334375)
• Expression of interferon induced protein with tetratricopeptide repeats 5 (IFIT5) is positively correlated with pathological characteristics, and predicts a poor prognosis of bladder cancer patients. (PMID:31164632)
• Development of bis-ANS-based modified fluorescence titration assay for IFIT/RNA studies. (PMID:32962861)
• IFIT5 Negatively Regulates the Type I IFN Pathway by Disrupting TBK1-IKKepsilon-IRF3 Signalosome and Degrading IRF3 and IKKepsilon. (PMID:33858962)
• Comprehensive analysis of the prognosis and biological significance for IFIT family in skin cutaneous melanoma. (PMID:34763233)

Cross-species orthologs

8 orthologs

Organism	Symbol	Gene ID
danio_rerio	ifit10	ENSDARG00000007467
danio_rerio	ifit15	ENSDARG00000043584
danio_rerio	ifit16	ENSDARG00000056976
danio_rerio	ifit8	ENSDARG00000057173
danio_rerio	ifit14	ENSDARG00000071012
danio_rerio		ENSDARG00000088069
danio_rerio	ifit11	ENSDARG00000090537
danio_rerio	ifit12	ENSDARG00000090977

Paralogs (4): IFIT3 (ENSG00000119917), IFIT2 (ENSG00000119922), IFIT1 (ENSG00000185745), IFIT1B (ENSG00000204010)

Protein

Protein identifiers

Interferon-induced protein with tetratricopeptide repeats 5 — Q13325 (reviewed: Q13325)

Alternative names: Interferon-induced 58 kDa protein, Retinoic acid- and interferon-inducible 58 kDa protein

All UniProt accessions (5): Q13325, A0A7P0T9H9, A0A7P0TB01, A0A7P0TBP9, A0A7P0Z4E6

UniProt curated annotations — full annotation on UniProt →

Function. Interferon-induced RNA-binding protein involved in the human innate immune response. Has a broad and adaptable RNA structure recognition important for RNA recognition specificity in antiviral defense. Binds precursor and processed tRNAs as well as poly-U-tailed tRNA fragments. Specifically binds single-stranded RNA bearing a 5’-triphosphate group (PPP-RNA), thereby acting as a sensor of viral single-stranded RNAs. Single-stranded PPP-RNAs, which lack 2’-O-methylation of the 5’ cap and bear a 5’-triphosphate group instead, are specific from viruses, providing a molecular signature to distinguish between self and non-self mRNAs by the host during viral infection. Directly binds PPP-RNA in a non-sequence-specific manner. Also recognizes and selectively binds AT-rich dsDNA. Additionally, as a mediator in innate immunity, positively regulates IKK-NFKB signaling by sinergizing the recruitment of IKK to MAP3K7.

Subunit / interactions. Monomer. Interacts with MAP3K7 and the components of the IKK core complex CHUK, IKBKB and IKBKG; the interaction synergizes the recruitment of IKK to MAP3K7 and enhances IKK phosphorylation.

Subcellular location. Cell projection. Ruffle membrane.

Domain organisation. RNA recognition is mediated by a convoluted intramolecular fold of the TPR repeats (TPR eddy), which scaffolds unique additional helices that form an RNA binding cleft. Undergoes a conformational change upon RNA-binding: unliganded exists in a more open conformation, facilitating RNA entry.

Induction. By interferons (IFNs).

Similarity. Belongs to the IFIT family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q13325-1	1	yes
Q13325-2	2

RefSeq proteins (1): NP_036552* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR011990	TPR-like_helical_dom_sf	Homologous_superfamily
IPR013105	TPR_2	Repeat
IPR019734	TPR_rpt	Repeat

Pfam: PF07719, PF13181, PF13374, PF13424

UniProt features (90 total): mutagenesis site 36, helix 29, repeat 8, site 7, strand 4, sequence conflict 2, chain 1, splice variant 1, turn 1, region of interest 1

Structure

Experimental structures (PDB)

6 structures.

PDB	Method	Resolution (Å)
4HOR	X-RAY DIFFRACTION	1.86
4J0U	X-RAY DIFFRACTION	1.97
4HOS	X-RAY DIFFRACTION	2
4HOQ	X-RAY DIFFRACTION	2.07
3ZGQ	X-RAY DIFFRACTION	2.2
4HOT	X-RAY DIFFRACTION	2.5

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q13325-F1	92.41	0.80

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (7): 33 (interaction with ppp-rna); 37 (interaction with ppp-rna); 41 (interaction with ppp-rna); 150 (interaction with ppp-rna); 186 (interaction with ppp-rna); 250 (interaction with ppp-rna); 288 (interaction with the 5’-triphosphate group of ppp-rna)

Mutagenesis-validated functional residues (36):

Position	Phenotype
33	no effect on rna-binding but changes size profile of rna bound. reduces ppp-rna-binding.
37	no effect on rna-binding but changes size profile of rna bound.
37	abolishes ppp-rna-binding.
41	no effect on rna-binding but changes size profile of rna bound. abolishes ppp-rna-binding.
48	inhibits rna-binding.
150	abolishes ppp-rna-binding.
150	inhibits rna-binding.
150	reduces rna-binding.
156	no effect on rna-binding. reduces ppp-rna-binding.
185–186	reduces binding to rna and dna.
186	abolishes rna-binding.
250	no effect on rna-binding but changes size profile of rna bound. abolishes ppp-rna-binding.
253–254	reduces binding to rna and dna.
253	abolishes rna-binding.
254	abolishes rna-binding.
257	reduces binding to rna and dna.
260	abolishes ppp-rna-binding.
284	strongly reduces binding to dsdna. no effect on ssrna binding.
287	reduces ppp-rna-binding.
288	abolishes rna-binding.
291	no effect rna-binding.
294	strongly reduces binding to dsdna. no effect on ssrna binding.
302	reduces rna-binding.
307	reduces rna-binding. 25 fold reduction in trna-binding.
309	reduces rna-binding.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-909733	Interferon alpha/beta signaling

MSigDB gene sets: 201 (showing top): BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOBP_RESPONSE_TO_PEPTIDE, GOBP_NEGATIVE_REGULATION_OF_VIRAL_PROCESS, GOBP_CANONICAL_NF_KAPPAB_SIGNAL_TRANSDUCTION, GOCC_RUFFLE, BEIER_GLIOMA_STEM_CELL_DN, MODULE_75, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, BLALOCK_ALZHEIMERS_DISEASE_UP, MODULE_171, DER_IFN_BETA_RESPONSE_UP, ZHAN_MULTIPLE_MYELOMA_LB_DN, GOBP_VIRAL_GENOME_REPLICATION, GOBP_VIRAL_LIFE_CYCLE

GO Biological Process (6): positive regulation of canonical NF-kappaB signal transduction (GO:0043123), negative regulation of viral genome replication (GO:0045071), innate immune response (GO:0045087), defense response to virus (GO:0051607), immune system process (GO:0002376), response to other organism (GO:0051707)

GO Molecular Function (7): tRNA binding (GO:0000049), RNA cap binding (GO:0000339), double-stranded DNA binding (GO:0003690), RNA binding (GO:0003723), single-stranded RNA binding (GO:0003727), poly(U) RNA binding (GO:0008266), protein binding (GO:0005515)

GO Cellular Component (8): cytosol (GO:0005829), plasma membrane (GO:0005886), actin cytoskeleton (GO:0015629), ruffle membrane (GO:0032587), apical part of cell (GO:0045177), IkappaB kinase complex (GO:0008385), membrane (GO:0016020), cell projection (GO:0042995)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Interferon Signaling	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
RNA binding	3
canonical NF-kappaB signal transduction	1
regulation of canonical NF-kappaB signal transduction	1
positive regulation of intracellular signal transduction	1
viral genome replication	1
regulation of viral genome replication	1
negative regulation of viral process	1
immune response	1
defense response to symbiont	1
defense response	1
response to virus	1
biological_process	1
response to external biotic stimulus	1
biological process involved in interspecies interaction between organisms	1
DNA binding	1
nucleic acid binding	1
poly-pyrimidine tract binding	1
binding	1
cytoplasm	1
membrane	1
cell periphery	1
cytoskeleton	1
ruffle	1
cell projection membrane	1
leading edge membrane	1
cytosol	1
serine/threonine protein kinase complex	1

Protein interactions and networks

STRING

1959 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
IFIT5	MX1	P20591	786
IFIT5	RIGI	O95786	748
IFIT5	IFIH1	Q9BYX4	739
IFIT5	IRF7	Q92985	726
IFIT5	OASL	Q15646	716
IFIT5	EIF2AK2	P19525	689
IFIT5	RSAD2	Q8WXG1	676
IFIT5	USP18	Q9UMW8	673
IFIT5	IRF1	P10914	661
IFIT5	CMPK2	Q5EBM0	645
IFIT5	TRIM25	Q14258	639
IFIT5	STAT2	P52630	634
IFIT5	MAVS	Q7Z434	627
IFIT5	OAS1	P00973	625
IFIT5	OAS2	P29728	614

IntAct

31 interactions, top by confidence:

A	B	Type	Score
MED4	MED19	psi-mi:“MI:2364”(proximity)	0.900
IFIT5	DMD	psi-mi:“MI:0914”(association)	0.530
	AP3D1	psi-mi:“MI:0914”(association)	0.460
IFIT5	SRPK2	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
IFIT5	SRPK1	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
A2M	IFIT5	psi-mi:“MI:0915”(physical association)	0.370
CDC37	IFIT5	psi-mi:“MI:0915”(physical association)	0.370
IFIT5	ECSIT	psi-mi:“MI:0915”(physical association)	0.370
IFIT3	IFIT5	psi-mi:“MI:0915”(physical association)	0.370
LONP1	IFIT5	psi-mi:“MI:0915”(physical association)	0.370
PRDX2	IFIT5	psi-mi:“MI:0915”(physical association)	0.370
IFIT5	RAD23A	psi-mi:“MI:0915”(physical association)	0.370
MAST1	IFIT5	psi-mi:“MI:0915”(physical association)	0.370
RNF32	IFIT5	psi-mi:“MI:0915”(physical association)	0.370
USP33	IFIT5	psi-mi:“MI:0914”(association)	0.350
rl3_rl3l_human	MPHOSPH10	psi-mi:“MI:0914”(association)	0.350
RBMS2	ZNF275	psi-mi:“MI:0914”(association)	0.350
IFIT5	SSB	psi-mi:“MI:0914”(association)	0.350
PRKRA	GTPBP10	psi-mi:“MI:0914”(association)	0.350
RBMS2		psi-mi:“MI:0914”(association)	0.350
RPL13	POLRMT	psi-mi:“MI:0914”(association)	0.350
ARHGAP19	IFIT5	psi-mi:“MI:0914”(association)	0.350
FAXC	HAT1	psi-mi:“MI:0914”(association)	0.350
IFIT5	CAND2	psi-mi:“MI:0914”(association)	0.350
LIN28A	GTPBP10	psi-mi:“MI:0914”(association)	0.350
TGFBRAP1	CCDC85C	psi-mi:“MI:0914”(association)	0.350
SLC40A1	UBR5	psi-mi:“MI:0914”(association)	0.350
SLC4A1	UPK3BL1	psi-mi:“MI:0914”(association)	0.350
TTC3	IFIT5	psi-mi:“MI:0915”(physical association)	0.000
SARAF	IFIT5	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (110): IFIT5 (Affinity Capture-MS), IFIT5 (Proximity Label-MS), KCTD6 (Affinity Capture-MS), RNF41 (Affinity Capture-MS), CRKL (Affinity Capture-MS), DMD (Affinity Capture-MS), IKBKB (Affinity Capture-Western), MAP3K7 (Affinity Capture-Western), CHUK (Affinity Capture-Western), IKBKG (Affinity Capture-Western), CHUK (Reconstituted Complex), IKBKG (Reconstituted Complex), IFIT5 (Affinity Capture-MS), IFIT5 (Affinity Capture-MS), IFIT5 (Proximity Label-MS)

ESM2 similar proteins: A2AQW0, A2VE39, D2HRF1, E1BVR9, E7F590, F1ND48, F1QWA8, F4IDS7, F4IVI0, O02697, O35099, O94952, P09914, P42338, P48736, Q13325, Q21029, Q3V3E1, Q4R3W5, Q4R5F5, Q5F204, Q5IH14, Q5R5S1, Q5R981, Q5T764, Q5T8I9, Q5U2Z5, Q6DFJ6, Q6NX27, Q6YXW6, Q80V94, Q8BTI9, Q8N1G2, Q8VZM1, Q91XL9, Q94E75, Q99683, Q99MV5, Q9BPX3, Q9BXW6

Diamond homologs: A5A6J9, O14879, P09913, P09914, Q13325, Q4R5F5, Q5T764, Q60462, Q64112, Q64282, Q64345

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

54 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	49
Likely benign	2
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

240 predictions. Top by Δscore:

Variant	Effect	Δscore
10:89414800:TGAGG:T	donor_loss	1.0000
10:89414801:GAG:G	donor_gain	1.0000
10:89414802:AGGTA:A	donor_loss	1.0000
10:89414803:GGTAA:G	donor_loss	1.0000
10:89414804:G:GG	donor_gain	1.0000
10:89414804:GTAA:G	donor_loss	1.0000
10:89414799:ATGAG:A	donor_gain	0.9900
10:89414800:TGAG:T	donor_gain	0.9900
10:89414801:GAGG:G	donor_gain	0.9900
10:89414802:AG:A	donor_gain	0.9900
10:89414803:GG:G	donor_gain	0.9900
10:89414805:T:A	donor_loss	0.9900
10:89417203:A:AG	acceptor_gain	0.9900
10:89417204:G:GG	acceptor_gain	0.9900
10:89417204:GT:G	acceptor_gain	0.9900
10:89417204:GTGAA:G	acceptor_gain	0.9900
10:89417203:AGT:A	acceptor_gain	0.9800
10:89417204:GTG:G	acceptor_gain	0.9800
10:89415443:GGTC:G	donor_gain	0.9600
10:89415220:ACC:A	donor_gain	0.9500
10:89417200:GACA:G	acceptor_loss	0.9400
10:89417201:ACAGT:A	acceptor_loss	0.9400
10:89417203:AGTG:A	acceptor_loss	0.9400
10:89417204:G:GA	acceptor_loss	0.9400
10:89417204:GTGA:G	acceptor_gain	0.9400
10:89415444:GTC:G	donor_gain	0.9300
10:89415445:TCT:T	donor_gain	0.9300
10:89417195:T:G	acceptor_loss	0.9300
10:89417194:A:AG	acceptor_loss	0.8800
10:89415138:GG:G	donor_gain	0.8700

AlphaMissense

3183 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:89417686:T:C	F163L	0.987
10:89417688:T:A	F163L	0.987
10:89417688:T:G	F163L	0.987
10:89418352:T:C	F385L	0.986
10:89418354:T:A	F385L	0.986
10:89418354:T:G	F385L	0.986
10:89417257:T:C	F20L	0.985
10:89417259:T:A	F20L	0.985
10:89417259:T:G	F20L	0.985
10:89418067:G:A	G290R	0.985
10:89418067:G:C	G290R	0.985
10:89417965:G:C	A256P	0.984
10:89417971:T:C	F258L	0.982
10:89417973:C:A	F258L	0.982
10:89417973:C:G	F258L	0.982
10:89418068:G:A	G290E	0.982
10:89417674:G:C	A159P	0.981
10:89417741:C:A	A181D	0.980
10:89417818:G:C	A207P	0.980
10:89418166:G:C	A323P	0.979
10:89418233:C:A	A345D	0.978
10:89418347:G:A	G383D	0.978
10:89417740:G:C	A181P	0.977
10:89417496:C:A	N99K	0.976
10:89417496:C:G	N99K	0.976
10:89417263:T:A	W22R	0.974
10:89417263:T:C	W22R	0.974
10:89417864:C:A	A222E	0.974
10:89417966:C:A	A256D	0.973
10:89417867:T:C	L223P	0.972

dbSNP variants (sampled 300 via entrez): RS1000206130 (10:89420849 T>A,C), RS1000297209 (10:89413743 A>C,T), RS1001609230 (10:89414512 C>G,T), RS1001903955 (10:89420581 C>T), RS1002168120 (10:89420926 A>G), RS1002610565 (10:89415357 T>C), RS1002744006 (10:89415797 C>T), RS1002747842 (10:89415148 C>G,T), RS1003030136 (10:89418945 C>T), RS1003609258 (10:89416766 G>A), RS1003748075 (10:89416540 T>C), RS1004202063 (10:89419659 A>C), RS1004256458 (10:89419210 T>C), RS1005011911 (10:89414701 G>A,C,T), RS1005211298 (10:89421255 G>A,C)

Disease associations

OMIM: gene MIM:616135 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

45 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression	7
sodium arsenite	decreases expression, increases abundance, increases expression	3
Estradiol	affects cotreatment, increases expression	3
Lipopolysaccharides	increases expression, affects reaction, affects response to substance, affects expression	2
Nickel	increases expression	2
Cyclosporine	decreases expression, increases expression	2
aristolochic acid I	decreases expression	1
dicrotophos	decreases expression	1
trichostatin A	increases expression	1
perfluorooctanoic acid	decreases expression	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
hydroquinone	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
perfluorooctane sulfonic acid	decreases expression	1
perfluoro-n-nonanoic acid	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	increases expression, affects cotreatment	1
dorsomorphin	affects cotreatment, increases expression	1
jinfukang	decreases expression	1
MT19c compound	increases expression	1
Temozolomide	increases expression	1
Air Pollutants	decreases expression, increases abundance	1
Arsenic	increases abundance, increases expression	1
Benzo(a)pyrene	increases expression	1
Carbamazepine	affects expression	1
Ivermectin	decreases expression	1
Methyl Methanesulfonate	decreases expression	1
Plant Extracts	affects expression, affects reaction	1
Quercetin	decreases expression	1
Ribonucleotides	affects binding	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1FX	Abcam A-549 IFIT5 KO 2	Cancer cell line	Male
CVCL_B2NF	Abcam A-549 IFIT5 KO 1	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.